FDA ApprovedFDA Approves Zidesamtinib for ROS1-Positive Non-Small Cell Lung CancerThe FDA approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive NSCLC previously treated with at least one ROS1 tyrosine kinase inhibitor.July 27, 2026
FDA ApprovedFDA Approves Gedatolisib Combination for Metastatic Breast CancerThe FDA approved the gedatolisib + fulvestrant combination for patients with endocrine-resistant HR+/HER2- metastatic breast cancer.July 17, 2026
FDA ApprovedA New FDA Approval in Triple-Negative Breast Cancer: Datopotamab Deruxtecan (Datroway) Gets the Green Light!The FDA approved datopotamab deruxtecan-dlnk (Datroway) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) not eligible for PD-1/PD-L1 inhibitor therapy.June 23, 2026
A New Era in Breast Cancer Monitoring: Can Blood Tests Warn of Disease Earlier?A study published in Nature Communications reports that methylation-based ctDNA (liquid biopsy) monitoring in hormone receptor–positive, HER2-negative metastatic breast cancer can signal disease progression around 6 months before imaging.June 22, 2026
FDA ApprovedA Targeted FDA Approval in Prostate Cancer: Green Light for the Capivasertib + Abiraterone Combination!The FDA approved capivasertib (Truqap) in combination with abiraterone and prednisone for PTEN-deficient metastatic (androgen pathway modulation–naïve/–sensitive) prostate cancer, as determined by an FDA-authorized test.June 18, 2026
FDA ApprovedAn Important FDA Approval in Ovarian Cancer: Green Light for the Relacorilant + Nab-Paclitaxel Combination!The FDA approved the glucocorticoid receptor antagonist relacorilant in combination with nab-paclitaxel for previously treated platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer.June 16, 2026
FDA ApprovedA Breakthrough FDA Approval in Kidney Cancer: Green Light for the Belzutifan + Pembrolizumab Combination!The FDA approved the belzutifan + pembrolizumab combination as adjuvant (post-surgery) therapy for clear cell renal cell carcinoma (ccRCC) patients at high risk of recurrence.June 15, 2026
Prof. Dr. Mutlu DemirayMedical OncologyProf. Dr. Mutlu DemirayMedical Oncology
